What gaps exist in current research on cannabis for AS? 

Despite growing interest, medical cannabis development for ankylosing spondylitis still faces several challenges. While many patients report symptom relief, clinical evidence remains patchy. Much of the current data stems from small-scale observational studies rather than robust, controlled trials, creating a need for broader, more standardised investigations. 

A major hurdle lies in translating anecdotal outcomes into validated treatment pathways. Variability in product quality, limited patient subgroup studies, and a lack of standardised technology use in data collection all restrict progress. These limitations also slow down the design of future applications, including more targeted therapies and new medications. 

Priority Areas for Research Expansion 

Here’s where research needs to catch up to patient demand: 

Large-scale clinical trials 

More diverse and longitudinal studies are needed to support safe, effective medical cannabis development. 

Data integration technologies 

Incorporating real-time tracking tools and AI could help address gaps in symptom-response mapping. 

Product consistency and safety 

Rigorous testing and regulation are needed to make new medications dependable and widely available. 

Exploration of under-represented symptoms 

Fatigue, mental health, and quality-of-life impacts are often overlooked in current cannabis research. 

Visit providers like LeafEase to stay informed on the evolving science and how you can engage with safer, evidence-informed medical cannabis development. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Ankylosing Spondylitis  and medical cannabis.